Monitoring CBC every 2 weeks when initiating new therapy is reasonable. This ensures that phlebotomy is not required and that WBC and platelet counts are also well-controlled. Monitoring for significant cytopenias, which can occur as a result of therapy or in some cases progression to myelofibrosis, is also important. Once a patient is stable, reducing follow-up to once monthly and then every 3 months is generally acceptable.